Antibacterial Therapies Drug Development Pipeline Review, 2017

GBI Research
418 Pages - GBI10562
$3,995.00

Summary

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.

There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.

Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the body’s immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.

The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

- Which companies are the most active within the pipeline for antibacterial drugs?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

'

Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 16
Introduction 20
GBI Research Report Coverage 20
Tuberculosis Overview 20
Pneumonia 20
Methicillin-Resistant Staphylococcus aureus (MRSA) 21
Therapeutics Development 22
Tuberculosis 22
Pneumonia 24
Methicillin-Resistant Staphylococcus aureus (MRSA) 33
Therapeutics under Development by Companies 38
Tuberculosis 38
Pneumonia 41
Methicillin-Resistant Staphylococcus aureus (MRSA) 50
Therapeutics under Investigation by Universities/Institutes 55
Tuberculosis 55
Pneumonia 57
Methicillin-Resistant Staphylococcus aureus (MRSA) 60
Pipeline Products Glance 62
Tuberculosis 62
Pneumonia 65
Methicillin-Resistant Staphylococcus aureus (MRSA) 79
Products under Development by Companies 83
Tuberculosis 83
Pneumonia 86
Methicillin-Resistant Staphylococcus aureus (MRSA) 94
Products under Investigation by Universities/Institutes 101
Tuberculosis 101
Pneumonia 104
Methicillin-Resistant Staphylococcus aureus (MRSA) 106
Companies Involved in Therapeutics Development 109
Tuberculosis 109
Pneumonia 142
Methicillin-Resistant Staphylococcus aureus (MRSA) 203
Therapeutics Assessment 252
Tuberculosis 252
Pneumonia 263
Methicillin-Resistant Staphylococcus aureus (MRSA) 311
Dormant Projects 339
Tuberculosis 339
Pneumonia 343
Methicillin-Resistant Staphylococcus aureus (MRSA) 351
Discontinued Products 357
Tuberculosis 357
Pneumonia 357
Methicillin-Resistant Staphylococcus aureus (MRSA) 359
Product Development Milestones 360
Tuberculosis 360
Pneumonia 373
Methicillin-Resistant Staphylococcus aureus (MRSA) 405
Appendix 417
Methodology 417
Coverage 417
Secondary Research 417
Primary Research 417
Expert Panel Validation 417
Contact Us 417
Disclaimer 418

List of Tables
Number of Products under Development for Tuberculosis 22
Number of Products under Development for Tuberculosis - Comparative Analysis 23
Number of Products under Development for Community Acquired Pneumonia 24
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 25
Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 26
Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 28
Number of Products under Development for Pseudomonas aeruginosa Infections 29
Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis 30
Number of Products under Development for Klebsiella pneumoniae Infections 31
Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis 32
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis 34
Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis 37
Number of Products under Development by Companies, Tuberculosis 38
Number of Products under Development by Companies, Community Acquired Pneumonia 41
Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 43
Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 45
Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46
Number of Products under Development by Companies, Klebsiella pneumoniae Infections 49
Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 50
Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 53
Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 54
Number of Products under Investigation by Universities/Institutes, Tuberculosis 55
Number of Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP) 57
Number of Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP) 57
Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 58
Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 59
Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 60
Number of Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 61
Comparative Analysis by Late Stage Development, Tuberculosis 62
Comparative Analysis by Clinical Stage Development, Tuberculosis 63
Comparative Analysis by Early Stage Development, Tuberculosis 64
Comparative Analysis by Unknown Stage Development, Tuberculosis 65
Comparative Analysis by Late Stage Development, Community Acquired Pneumonia 65
Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia 66
Comparative Analysis by Early Stage Development, Community Acquired Pneumonia 67
Comparative Analysis by Late Stage Development, Hospital Acquired Pneumonia (HAP) 67
Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP) 68
Comparative Analysis by Early Stage Development, Hospital Acquired Pneumonia (HAP) 69
Comparative Analysis by Unknown Stage Development, Hospital Acquired Pneumonia (HAP) 69
Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP) 70
Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP) 71
Comparative Analysis by Early Stage Development, Ventilator Associated Pneumonia (VAP) 72
Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP) 73
Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections 74
Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections 75
Comparative Analysis by Early Stage Development, Pseudomonas aeruginosa Infections 76
Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections 77
Comparative Analysis by Late Stage Development, Klebsiella pneumoniae Infections 77
Comparative Analysis by Clinical Stage Development, Klebsiella pneumoniae Infections 78
Comparative Analysis by Early Stage Development, Klebsiella pneumoniae Infections 78
Comparative Analysis by Late Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79
Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79
Comparative Analysis by Early Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 80
Comparative Analysis by Unknown Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 81
Comparative Analysis by Clinical Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 81
Comparative Analysis by Early Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 81
Comparative Analysis by Clinical Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 81
Comparative Analysis by Early Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 82
Products under Development by Companies, Tuberculosis 83
Products under Development by Companies, Community Acquired Pneumonia 86
Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 88
Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 89
Products under Development by Companies, Pseudomonas aeruginosa Infections 89
Products under Development by Companies, Klebsiella pneumoniae Infections 93
Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 94
Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 100
Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 100
Products under Investigation by Universities/Institutes, Tuberculosis 101
Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP) 104
Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP) 104
Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 104
Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 106
Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 106
Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 108
Tuberculosis - Pipeline by Abera Bioscience AB, 109
Tuberculosis - Pipeline by Akthelia Pharmaceuticals Limited, 109
Tuberculosis - Pipeline by Alvogen Korea Co., Ltd., 110
Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., 111
Tuberculosis - Pipeline by Archivel Farma S.L., 111
Tuberculosis - Pipeline by AstraZeneca Plc, 112
Tuberculosis - Pipeline by Beech Tree Labs, Inc., 113
Tuberculosis - Pipeline by BioDiem Ltd, 113
Tuberculosis - Pipeline by BioLingus AG, 114
Tuberculosis - Pipeline by Biomar Microbial Technologies, 114
Tuberculosis - Pipeline by Bioversys AG, 115
Tuberculosis - Pipeline by Celgene Corporation, 115
Tuberculosis - Pipeline by Cellceutix Corporation, 116
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., 116
Tuberculosis - Pipeline by Crestone, Inc., 117
Tuberculosis - Pipeline by Dafra Pharma International Ltd., 117
Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited, 118
Tuberculosis - Pipeline by Demuris Limited, 118
Tuberculosis - Pipeline by Eisai Co., Ltd., 119
Tuberculosis - Pipeline by Eli Lilly and Company, 120
Tuberculosis - Pipeline by Ensol Biosciences Inc., 120
Tuberculosis - Pipeline by EpiVax, Inc., 121
Tuberculosis - Pipeline by FIT Biotech Oy, 121
Tuberculosis - Pipeline by GangaGen Inc., 122
Tuberculosis - Pipeline by GlaxoSmithKline Plc, 122
Tuberculosis - Pipeline by Globeimmune, Inc., 123
Tuberculosis - Pipeline by Hager Biosciences, LLC, 123
Tuberculosis - Pipeline by Hsiri Therapeutics LLC, 124
Tuberculosis - Pipeline by Imaxio SA, 124
Tuberculosis - Pipeline by Immunitor, Inc., 125
Tuberculosis - Pipeline by ImmunoBiology Limited, 125
Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc., 126
Tuberculosis - Pipeline by Johnson & Johnson, 126
Tuberculosis - Pipeline by Lakewood-Amedex Inc, 127
Tuberculosis - Pipeline by Lipotek Pty Ltd., 127
Tuberculosis - Pipeline by Matinas BioPharma Holdings, Inc. , 128
Tuberculosis - Pipeline by Microbion Corporation, 128
Tuberculosis - Pipeline by Microbiotix, Inc., 129
Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd, 129
Tuberculosis - Pipeline by Novartis AG, 130
Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals, LLC, 130
Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., 131
Tuberculosis - Pipeline by QureTech Bio AB, 131
Tuberculosis - Pipeline by Recce Pty Ltd, 132
Tuberculosis - Pipeline by Rodos BioTarget GmbH, 132

List of Figures
Number of Products under Development for Tuberculosis 22
Number of Products under Development for Tuberculosis - Comparative Analysis 23
Number of Products under Development for Community Acquired Pneumonia 24
Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 26
Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 28
Number of Products under Development for Pseudomonas aeruginosa Infections 29
Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis 30
Number of Products under Development for Klebsiella pneumoniae Infections 31
Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis 32
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis 34
Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis 37
Number of Products under Development by Companies, Tuberculosis 38
Number of Products under Development by Companies, Community Acquired Pneumonia 41
Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 42
Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 44
Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46
Number of Products under Development by Companies, Klebsiella pneumoniae Infections 48
Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 50
Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 53
Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 54
Number of Products under Investigation by Universities/Institutes, Tuberculosis 55
Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 57
Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 59
Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 60
Comparative Analysis by Late Stage Development, Tuberculosis 62
Comparative Analysis by Clinical Stage Development, Tuberculosis 63
Comparative Analysis by Early Stage Products, Tuberculosis 64
Comparative Analysis by Late Stage Development, Community Acquired Pneumonia 65
Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia 66
Comparative Analysis by Early Stage Products, Community Acquired Pneumonia 67
Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP) 68
Comparative Analysis by Early Stage Products, Hospital Acquired Pneumonia (HAP) 69
Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP) 70
Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP) 71
Comparative Analysis by Early Stage Products, Ventilator Associated Pneumonia (VAP) 72
Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP) 73
Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections 74
Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections 75
Comparative Analysis by Early Stage Products, Pseudomonas aeruginosa Infections 76
Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections 77
Comparative Analysis by Early Stage Products, Klebsiella pneumoniae Infections 78
Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79
Comparative Analysis by Early Stage Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 80
Comparative Analysis by Early Stage Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 82
Assessment by Monotherapy Products, Tuberculosis 252
Assessment by Combination Products, Tuberculosis 253
Number of Products by Top 10 Targets, Tuberculosis 254
Number of Products by Stage and Top 10 Targets, Tuberculosis 254
Number of Products by Top 10 Mechanism of Actions, Tuberculosis 257
Number of Products by Stage and Top 10 Mechanism of Actions, Tuberculosis 257
Number of Products by Top 10 Routes of Administration, Tuberculosis 260
Number of Products by Stage and Top 10 Routes of Administration, Tuberculosis 260
Number of Products by Top 10 Molecule Types, Tuberculosis 262
Number of Products by Stage and Top 10 Molecule Types, Tuberculosis 262
Assessment by Monotherapy Products, Community Acquired Pneumonia 263
Number of Products by Targets, Community Acquired Pneumonia 264
Number of Products by Stage and Targets, Community Acquired Pneumonia 265
Number of Products by Mechanism of Actions, Community Acquired Pneumonia 266
Number of Products by Stage and Mechanism of Actions, Community Acquired Pneumonia 266
Number of Products by Routes of Administration, Community Acquired Pneumonia 267
Number of Products by Stage and Routes of Administration, Community Acquired Pneumonia 268
Number of Products by Molecule Types, Community Acquired Pneumonia 269
Number of Products by Stage and Top 10 Molecule Types, Community Acquired Pneumonia 269
Assessment by Monotherapy Products, Hospital Acquired Pneumonia (HAP) 270
Assessment by Combination Products, Hospital Acquired Pneumonia (HAP) 271
Number of Products by Top 10 Targets, Hospital Acquired Pneumonia (HAP) 272
Number of Products by Stage and Top 10 Targets, Hospital Acquired Pneumonia (HAP) 272
Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP) 274
Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP) 274
Number of Products by Routes of Administration, Hospital Acquired Pneumonia (HAP) 276
Number of Products by Stage and Routes of Administration, Hospital Acquired Pneumonia (HAP) 276
Number of Products by Molecule Types, Hospital Acquired Pneumonia (HAP) 277
Number of Products by Stage and Molecule Types, Hospital Acquired Pneumonia (HAP) 278
Assessment by Monotherapy Products, Ventilator Associated Pneumonia (VAP) 279
Assessment by Combination Products, Ventilator Associated Pneumonia (VAP) 280
Number of Products by Top 10 Targets, Ventilator Associated Pneumonia (VAP) 281
Number of Products by Stage and Top 10 Targets, Ventilator Associated Pneumonia (VAP) 282
Number of Products by Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP) 284
Number of Products by Stage and Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP) 285
Number of Products by Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP) 287
Number of Products by Stage and Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP) 288
Number of Products by Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP) 289
Number of Products by Stage and Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP) 290
Assessment by Monotherapy Products, Pseudomonas aeruginosa Infections 291
Assessment by Combination Products, Pseudomonas aeruginosa Infections 292
Number of Products by Top 10 Targets, Pseudomonas aeruginosa Infections 293
Number of Products by Stage and Top 10 Targets, Pseudomonas aeruginosa Infections 293
Number of Products by Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections 295
Number of Products by Stage and Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections 296
Number of Products by Routes of Administration, Pseudomonas aeruginosa Infections 299
Number of Products by Stage and Routes of Administration, Pseudomonas aeruginosa Infections 299
Number of Products by Top 10 Molecule Types, Pseudomonas aeruginosa Infections 301
Number of Products by Stage and Top 10 Molecule Types, Pseudomonas aeruginosa Infections 301
Assessment by Monotherapy Products, Klebsiella pneumoniae Infections 303
Number of Products by Top 10 Targets, Klebsiella pneumoniae Infections 304
Number of Products by Stage and Top 10 Targets, Klebsiella pneumoniae Infections 304
Number of Products by Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections 306
Number of Products by Stage and Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections 306
Number of Products by Routes of Administration, Klebsiella pneumoniae Infections 308
Number of Products by Stage and Routes of Administration, Klebsiella pneumoniae Infections 308
Number of Products by Molecule Types, Klebsiella pneumoniae Infections 309
Number of Products by Stage and Molecule Types, Klebsiella pneumoniae Infections 310
Assessment by Monotherapy Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 311
Assessment by Combination Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 312
Number of Products by Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 313
Number of Products by Stage and Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 313
Number of Products by Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 316
Number of Products by Stage and Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 316
Number of Products by Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 319
Number of Products by Stage and Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 319
Number of Products by Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 321
Number of Products by Stage and Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 321
Assessment by Monotherapy Products, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 323
Number of Products by Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 324
Number of Products by Stage and Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 324
Number of Products by Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 325
Number of Products by Stage and Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 326
Number of Products by Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 327
Number of Products by Stage and Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 327
Number of Products by Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 329
Number of Products by Stage and Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 329
Assessment by Monotherapy Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 330
Number of Products by Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 331
Number of Products by Stage and Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 331
Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 333
Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 333
Number of Products by Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 335
Number of Products by Stage and Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 335
Number of Products by Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 337
Number of Products by Stage and Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 33

$3,995.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports